论文部分内容阅读
目的探讨米非司酮联合桂枝茯苓胶囊对子宫内膜异位症患者血清CA125、CA199及性激素水平的影响。方法选取2015年6月至2016年6月我院收治的子宫内膜异位症患者96例,随机分为观察组和对照组,每组48例。给予对照组患者米非司酮,观察组在对照组的基础上加用桂枝茯苓胶囊,比较两组患者临床疗效,治疗前后的血清促卵泡生成素(FSH)、黄体生产素(LH)、雌激素(E_2)、孕酮(P)以及CA125、CA199水平,并比较两组不良反应发生情况。结果观察组总有效率(95.83%)显著高于对照组(77.08%),差异有统计学意义(P<0.05);治疗后,观察组CA125、CA199分别为(11.62±3.20)U/ml、(17.33±2.23)U/ml,FSH、LH、E_2、P分别为(5.20±1.34)IU/L、(5.96±1.71)IU/L、(104.44±31.71)pmol/L、(0.40±0.35)nmol/L,均低于治疗前,且低于同期对照组,差异均有统计学意义(P<0.05);观察组不良反应发生率为4.17%,显著低于对照组(16.67%),差异有统计学意义(P<0.05)。结论米非司酮联合桂枝茯苓胶囊治疗子宫内膜异位症的疗效显著,可有效降低患者血清CA125、CA199及性激素水平,安全可靠。
Objective To investigate the effects of mifepristone and Guizhi Fuling capsule on serum CA125, CA199 and sex hormone levels in patients with endometriosis. Methods Ninety-six patients with endometriosis admitted to our hospital from June 2015 to June 2016 were randomly divided into observation group and control group, 48 cases in each group. The patients in the control group were given mifepristone. The observation group was treated with Guizhi Fuling capsule on the basis of the control group. The clinical effects, serum FSH, LH, Estrogen (E2), progesterone (P) and CA125, CA199 levels, and compare the two groups of adverse reactions. Results The total effective rate (95.83%) in the observation group was significantly higher than that in the control group (77.08%) (P <0.05). After treatment, the levels of CA125 and CA199 in the observation group were (11.62 ± 3.20) U / ml, (5.20 ± 1.34) IU / L, (5.96 ± 1.71) IU / L, (104.44 ± 31.71) pmol / L and (0.40 ± 0.35) nmol / L, all of which were lower than those of the control group and lower than that of the control group (P <0.05). The incidence of adverse reactions in the observation group was 4.17%, significantly lower than that of the control group (16.67%), There was statistical significance (P <0.05). Conclusion Mifepristone and Guizhi Fuling Capsule have significant therapeutic effect on endometriosis, which can effectively reduce the levels of serum CA125, CA199 and sex hormones, and are safe and reliable.